Moderna, Inc.(MRNA) Stock Research - Grey Stern Research

Moderna, Inc. (MRNA) Stock Analysis

$34.77 (0.90%)

MRNA Financial Performance


Use the table below to view Moderna, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $34.77 -
52 Week Low $31.94 -
52 Week High $170.47 -
Market Cap $13.4 Billion 2/17
Gross Margin 72% 7/17
Profit Margin 1% 5/17
EBITDA margin -4% 4/17
Q3 - 2024 Revenue $1.9 Billion 2/17
Q3 - 2024 Earnings $13.0 Million 5/17
Q3 - 2024 Free Cash Flow -$1.7 Million 16/17
Trailing 4 Quarters Revenue $5.1 Billion 2/17
Trailing 4 Quarters Earnings -$2.2 Billion 17/17
Quarterly Earnings Growth 100% 4/17
Annual Earnings Growth 71% 5/17
Quarterly Revenue Growth 2% 6/17
Annual Revenue Growth 77% 5/17
Cash On Hand $1.6 Billion 2/17
Short Term Debt $0 12/17
Long Term Debt $1.3 Billion 2/17

Moderna, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Moderna, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 4/17
PS 2.63 6/17
PB 1.12 6/17
PC 8.14 8/17
Liabilities to Equity 0.32 7/17
ROA -0.14 6/17
ROE -0.19 10/17
Current Ratio 4.08 7/17
Quick Ratio 0.42 13/17
Long Term Debt to Equity 0.11 6/17
Debt to Equity 0.11 6/17
Burn Rate 41.98 1/17
Cash to Cap 0.12 10/17
CCR -132.08 16/17
EV to EBITDA -186.29 17/17
EV to Revenue 2.57 6/17

Company Details

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

CEO: Mr. Stephane Bancel

Website: https://www.modernatx.com

Address: 200 Technology Sq Cambridge, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Biotechnology

Moderna, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Moderna, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Novavax, Inc. NVAX $1.4 Billion
Vertex Pharmaceuticals Incorporated VRTX $109.3 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Editas Medicine, Inc. EDIT $100.7 Million
Intellia Therapeutics, Inc. NTLA $989.0 Million
Krystal Biotech, Inc. KRYS $4.2 Billion
CohBar, Inc. CWBR $1.2 Million
AVROBIO, Inc. AVRO $5.2 Million
Hepion Pharmaceuticals, Inc. HEPA $3.0 Million
Beam Therapeutics Inc. BEAM $1.9 Billion
CureVac N.V. CVAC $912.9 Million
Rain Therapeutics Inc. RAIN $28.8 Million
Elevation Oncology, Inc. ELEV $43.0 Million
Ocean Biomedical, Inc. OCEA $21.0 Million
Enveric Biosciences, Inc. ENVB $3.6 Million
Ginkgo Bioworks Holdings, Inc. DNA $534.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement

Latest News

MRNA Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 1.9 Billion $13.0 Million
Q2 2024 $ 241.0 Million -$1.3 Billion
Q1 2024 $ 167.0 Million -$1.2 Billion
Q4 2023 $ 2.8 Billion $217.0 Million
Q3 2023 $ 1.8 Billion -$3.6 Billion
Q2 2023 $ 344.0 Million -$1.4 Billion
Q1 2023 $ 1.9 Billion $79.0 Million
Q4 2022 $ 5.1 Billion $1.5 Billion

View All

MRNA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $1.6 Billion $15.8 Billion $1.3 Billion $11.9 Billion
Q2 2024 $2.5 Billion $15.7 Billion $1.3 Billion $11.7 Billion
Q1 2024 $2.1 Billion $16.7 Billion $1.2 Billion $12.8 Billion
Q4 2023 $2.9 Billion $18.4 Billion $1.2 Billion $13.9 Billion
Q3 2023 $2.9 Billion $19.5 Billion $1.3 Billion $13.5 Billion
Q2 2023 $3.8 Billion $21.9 Billion $947.0 Million $16.9 Billion
Q1 2023 $3.4 Billion $24.1 Billion $927.0 Million $18.9 Billion
Q4 2022 $3.2 Billion $25.9 Billion $1.2 Billion $19.1 Billion

View All

MRNA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$1.7 Billion -$151.0 Million -$831.0 Million
Q2 2024 -$1.5 Billion -$182.0 Million $410.0 Million
Q1 2024 -$1.2 Billion -$196.0 Million -$856.0 Million
Q4 2023 $402.0 Million -$220.0 Million -$25.0 Million
Q3 2023 -$1.7 Billion -$140.0 Million -$869.0 Million
Q2 2023 -$1.1 Billion -$234.0 Million $361.0 Million
Q1 2023 -$1.3 Billion -$113.0 Million $244.0 Million
Q4 2022 $1.6 Billion -$92.0 Million $176.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions